TIA-1 expression in hairy cell leukemia

Modern Pathology

Volumn 17, Issue 7, 2004, Pages 840-846

  Mori, Naoyoshi ^a   Murakami, Yoshiko Idate ^a   Shimada, Satoko ^a   Iwamizu Watanabe, Sachiko ^a   Yamashita, Yoriko ^a   Hasegawa, Yuichi ^b   Kojima, Hiroshi ^b   Nagasawa, Toshiro ^b  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Cytotoxic protein; Hairy cell leukemia; TIA 1

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CD103 ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CYTOPLASM PROTEIN; CYTOTOXIC FACTOR; FMC7 ANTIGEN; GLYCOPROTEIN P 15095; GRANZYME B; INTERLEUKIN 2 RECEPTOR; PERFORIN; T LYMPHOCYTE ANTIGEN; T LYMPHOCYTE INTRACELLULAR ANTIGEN 1; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; CLINICAL ARTICLE; EXTRANODAL MARGINAL ZONE B CELL LYMPHOMA; FEMALE; FOLLICULAR LYMPHOMA; HAIRY CELL LEUKEMIA; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; MALE; MANTLE CELL LYMPHOMA; MEDIASTINAL LARGE CELL LYMPHOMA; MEDIASTINUM TUMOR; MYELOMA; NATURAL KILLER CELL; NODAL MARGINAL ZONE B CELL LYMPHOMA; PRIORITY JOURNAL; SPLEEN LYMPHOMA; SPLEEN TUMOR; T LYMPHOCYTE;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD11C; ANTIGENS, CD19; ANTIGENS, CD20; BONE MARROW CELLS; FEMALE; FLOW CYTOMETRY; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRIN ALPHA CHAINS; LEUKEMIA, HAIRY CELL; MALE; MICROSCOPY, IMMUNOELECTRON; MIDDLE AGED; POLY(A)-BINDING PROTEINS; PROTEIN BIOSYNTHESIS; PROTEINS; RNA-BINDING PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 3042535708     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3800129     Document Type: Article

References (48)

1. Griffiths GM, Mueller C. Expression of perforin and granzymes in vivo: potential diagnostic markers for activated cytotoxic cells. Immunol Today 1991;12:415-419.
2. Beck ARP, Medley QG, O'Brien S, et al. Structure, tissue distribution and genomic organization of the murine RRM-type RNA binding proteins TIA-1 and TIAR. Nucleic Acids Res 1993;21:3699-3704.
3. Kawakami A, Tian Q, Duan X, et al. Identification and functional characterization of a TIA-1-related protein. Proc Natl Acad Sci USA 1992;89:8681-8685.
4. Tian Q, Streuli M, Saito H, et al. A polyadenylate binding protein localized to the granules of cytolytic lymphocytes induces DNA fragmentation in target cells. Cell 1991;67:629-639.
5. Takeuchi Y, Nishimura T, Gao XH, et al. Perforin is expressed in CTL populations generated in vivo. Immunol Lett 1992;31:183-187.
6. Medley QG, Kedersha N, O'Brien S, et al. Characterization of GMP-17, a granule membrane protein that moves to the plasma membrane of natural killer cells following target cell recognition. Proc Natl Acad Sci USA 1996;93:685-689.
7. Shimane M, Tani K, Hibino H, et al. Significant expression of G-CSF-induced gene-1 (GIG-1) protein in myeloid cells and NK cells. J Leukoc Biol 1999;65:109-116.
8. Boulland M-L, Kanavaros P, Wechsler J, et al. Cytotoxic protein expression in natural killer cell lymphomas and in αβ and γδ peripheral T-cell lymphomas. J Pathol 1997;183:432-439.
9. Felger RE, Macon WR, Kinney MC, et al. TIA-1 expression in lymphoid neoplasms. Identification of subsets with cytotoxic T lymphocyte or natural killer cell differentiation. Am J Pathol 1997;150:1893-1900.
10. Yamashita Y, Yatabe Y, Tsuzuki T, et al. Perforin and granzyme expression in cytotoxic T-cell lymphomas. Mod Pathol 1998;11:313-323.
11. Yamashita Y, Nakamura S, Kagami Y, et al. Lennert's lymphoma. A variant of cytotoxic T-cell lymphoma? Am J Surg Pathol 2000;24:1627-1633.
12. Mori N, Yatabe Y, Oka K, et al. Expression of perforin in nasal lymphoma. Additional evidence of its natural killer cell derivation. Am J Pathol 1996;149:699-705.
13. Chan JK, Sin VC, Wong KF, et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood 1997;86:4501-4513.
14. Mori N, Yamashita Y, Tsuzuki T, et al. Lymphomatous features of aggressive NK cell leukemia/lymphoma with massive necrosis, haemophagocytosis and EB virus infection. Histopathology 2000;37:363-371.
15. Cooke CB, Krenacs L, Stetler-Stevenson M, et al. Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic γδ T-cell origin. Blood 1996;88:4265-4274.
16. Wu H, Wasik MA, Przybylski G, et al. Hepatosplenic gamma-delta T-cell lymphoma as a late-onset posttransplant lymphoproliferative disorder in renal transplant recipients. Am J Clin Pathol 2000;113:487-496.
17. Gaulard P, Bourquelot P, Kanavaros P, et al. Expression of the alpha/beta and gamma/delta T-cell receptors in 57 cases of peripheral T-cell lymphomas. Identification of a subset of γ/δ T-cell lymphomas. Am J Pathol 1990;137:617-628.
18. Gonzalez CL, Medeiros LJ, Braziel RM, et al. T-cell lymphoma involving subcutaneous tissue. A clinicopathologic entity commonly associated with hemophagocytic syndrome. Am J Surg Pathol 1991;15:17-27.
19. Salhany KE, Macon WR, Choi JK, et al. Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha/ beta and gamma/delta subtypes. Am J Surg Pathol 1998;22:881-893.
20. Chott A, Haedicke W, Mosberger L, et al. Most CD56+ intestinal lymphomas are CD8+CD5- T-cell lymphomas of monomorphic small to medium size histology. Am J Pathol 1998;153:1483-1490.
21. Krenacs L, Wellmann A, Sorbara L, et al. Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T- and null-cell type and Hodgkin's disease: evidence for distinct cellular origin. Blood 1997;89:980-989.
22. McLean IW, Nakane PK. Periodate-lysine-paraformaldehyde fixative: a new fixative for immunoelectron microscopy. J Histochem Cytochem 1974;22:1077-1083.
23. Tsunoda R, Terashima K, Takahashi K, et al. An ultrastructural study with enzyme-labeled antibody technique on immunoglobulin containing cells in human tonsils, especially in germinal centers. Acta Pathol Jpn 1978;28:53-75.
24. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody(PAP) procedures. J Histochem Cytochem 1981;29:577-580.
25. Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood 1958;13:609-630.
26. Yam LT, Li CY, Lam KW. Tartrate-resistant acid phosphatase isoenzyme in the reticulum cells of leukemic reticuloendotheliosis. N Engl J Med 1971;284:357-360.
27. Jaffe ES, Shevach EM, Frank MM, et al. Leukemic reticuloendotheliosis: Presence of a receptor for cytophilic antibody. Am J Med 1974;57:108-114.
28. Katayama I, Finkel HE. Leukemic reticuloendotheliosis. A clinicopathologic study with review of the literature. Am J Med 1974;157:115-126.
29. Naeim F, Smith GS. Leukemic reticuloendotheliosis. Cancer 1974;34:1813-1821.
30. King GW, Hurtubise PE, Sagone AL, et al. Leukemic reticuloendotheliosis. A study of the origin of the malignant cell. Am J Med 1975;59:411-416.
31. Katayama I, Yang JPS. Reassesment of a cytochemical test for differential diagnosis of leukemic reticuloendotheliosis. Am J Clin Pathol 1977;68:268-272.
32. Golomb HM, Vardiman JW. Response to splenectomy in 65 patients with hairy cell leukemia: an evaluation of spleen weight and bone marrow involvement. Blood 1983;61:349-352.
33. Schrek R, Donnelly WJ. Hairy cells in blood in lymphoreticular neoplastic disease and flagellated cells of normal lymph nodes. Blood 1966;27:199-211.
34. Bitter MA. Hairy cell leukemia and related disorders. In: Knowles DM (ed). Neoplastic Hematopathology, 2nd edn. Lippincott Williams & Wilkins: Baltimore, 2001, pp 1531-1555.
35. Foucar K, Catovsky D. Hairy cell leukemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JM (eds). World Health Organization Classification of Tumors. Tumors of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, 2001, pp 138-141.
36. Nanba K, Soban EJ, Bowling MC, et al. Splenic pseudosinuses and hepatic angiomatous lesions. Distinctive features of hairy cell leukemia. Am J Clin Pathol 1977;67:415-426.
37. Machii T, Tokumine Y, Inoue R, et al. Predominance of a distinct subtype of hairy cell leukemia in Japan. Leukemia 1993;7:181-186.
38. Shibayama H, Machii T, Yamaguchi M, et al. Early age onset of hairy cell leukemia presenting with leukocytosis. Int J Hematol 1996;64:287-290.
39. Yamaguchi M, Machii T, Shibayama H, et al. Immunophenotypic features and configuration of immunoglobulin genes in hairy cell leukemia-Japanese variant. Leukemia 1996;10:1390-1394.
40. Sainati L, Matutes E, Mulligan S, et al. A variant of hairy cell leukemia resistant to α-interferon. Clinical and phenotypic characteristics of 17 patients. Blood 1990;76:157-162.
41. Vardiman JW, Gilewski TA, Ratain MJ, et al. Evaluation of LeuM5(CD11c) in hairy cell leukemia by the alkaline phosphatase anti-alkaline phosphatase technique. Am J Clin Pathol 1988;90:250-256.
42. Schwarting R, Stein H, Wang CY. The monoclonal antibodies αS-HCL1(αLeu14) and αS-HCL3(αLeuM5) allow the diagnosis of hairy cell leukemia. Blood 1985;65:974-983.
43. Hsu S-M, Yang K, Jaffe ES. Hairy cell leukemia: a B cell neoplasm with a unique antigenic phenotype. Am J Clin Pathol 1983;80:421-428.
44. Foucar K. Chronic lymphoid leukemias and lymphoproliferative disorders. Mod Pathol 1999;12:141-150.
45. Gruber G, Schwarzmeier JD, Shehata M, et al. Basic fibroblast growth factor is expressed by CD19/CD11c-positive cells in hairy cell leukemia. Blood 1999;94:1077-1085.
46. Aziz KA, Till KJ, Chen H, et al. The role of autocrine FGF-2 in the distinctive bone marrow fibrosis of hairy cell leukemia (HCL). Blood 2003;102:1051-1056.
47. Janckila AJ, Gentile PS, Yam LT. Hemopoietic inhibition in hairy cell leukemia. Am J Hematol 1991;38:30-39.
48. Khalaf W, Maina C, Byers J, et al. Interferon-alpha 2b and vesnarinone influence levels of tumor necrosis factor-alpha, apoptosis, or interleukin 6 in ESKOL, a hairy cell leukemic cell line. A potential cytokine and oncogene relationship regulating apoptosis is suggested. Leuk Res 2002;26:169-177.